Cargando…

Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cells

SIMPLE SUMMARY: The anaplastic lymphoma kinase (ALK) and rearranged during transfection (RET) receptor tyrosine kinases (RTKs) are expressed in both the developing neural crest and the pediatric cancer neuroblastoma. Moreover, ALK is mutated in approximately 10% of neuroblastomas. Here, we investiga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siaw, Joachim T., Gabre, Jonatan L., Uçkun, Ezgi, Vigny, Marc, Zhang, Wancun, Van den Eynden, Jimmy, Hallberg, Bengt, Palmer, Ruth H., Guan, Jikui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071449/ https://www.ncbi.nlm.nih.gov/pubmed/33921066 http://dx.doi.org/10.3390/cancers13081909

Ejemplares similares

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
por: Siaw, Joachim T., et al.
Publicado: (2016)

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
por: Szydzik, Joanna, et al.
Publicado: (2021)

Chromosome Imbalances in Neuroblastoma—Recent Molecular Insight into Chromosome 1p-deletion, 2p-gain, and 11q-deletion Identifies New Friends and Foes for the Future
por: Guan, Jikui, et al.
Publicado: (2021)

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)

Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent
por: Guan, Jikui, et al.
Publicado: (2016)

Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation
por: Guan, Jikui, et al.
Publicado: (2017)

IGF1R Contributes to Cell Proliferation in ALK-Mutated Neuroblastoma with Preference for Activating the PI3K-AKT Signaling Pathway
por: Guan, Jikui, et al.
Publicado: (2023)

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
por: Borenäs, Marcus, et al.
Publicado: (2021)

ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression
por: Chuang, Tzu-Po, et al.
Publicado: (2023)

Targeting anaplastic lymphoma kinase in neuroblastoma
por: Umapathy, Ganesh, et al.
Publicado: (2019)

Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment
por: Mazot, Pierre, et al.
Publicado: (2012)

Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation
por: Treis, Diana, et al.
Publicado: (2022)

Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration
por: Huang, Hao, et al.
Publicado: (2021)

Expression of ret Proto‐oncogene in Human Neuroblastomas
por: Nagao, Minako, et al.
Publicado: (1990)

Neuroblastoma xenograft models demonstrate the therapeutic potential of (177)Lu-octreotate
por: Romiani, Arman, et al.
Publicado: (2021)

The role of the ShcD and RET interaction in neuroblastoma survival and migration
por: Mabruk, Zeanap A., et al.
Publicado: (2018)

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
por: Cervantes-Madrid, Diana, et al.
Publicado: (2019)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

Plasticity in Neuroblastoma Cell Identity Defines a Noradrenergic-to-Mesenchymal Transition (NMT)
por: Gautier, Margot, et al.
Publicado: (2021)

Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene.
por: Iwamoto, T., et al.
Publicado: (1993)

Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma
por: Thirant, Cécile, et al.
Publicado: (2023)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo
por: Chen, Zhenghu, et al.
Publicado: (2017)

Activated ALK signals through the ERK–ETV5–RET pathway to drive neuroblastoma oncogenesis
por: Lopez-Delisle, Lucille, et al.
Publicado: (2018)

Quantitative Phosphoproteomic Analysis Identifies Activation of the RET and IGF-1R/IR Signaling Pathways in Neuroblastoma
por: DeNardo, Bradley D., et al.
Publicado: (2013)

FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
por: Guan, Jikui, et al.
Publicado: (2015)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

A Cross-Talk between TrkB and Ret Tyrosine Kinases Receptors Mediates Neuroblastoma Cells Differentiation
por: Esposito, Carla Lucia, et al.
Publicado: (2008)

Chromatin and DNA methylation dynamics during retinoic acid-induced RET gene transcriptional activation in neuroblastoma cells
por: Angrisano, T., et al.
Publicado: (2011)

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma
por: Cazes, Alex, et al.
Publicado: (2014)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma
por: Chand, Damini, et al.
Publicado: (2013)

Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitization
por: Schmutzler, Brian S, et al.
Publicado: (2011)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

Anaplastic lymphoma kinase: signalling in development and disease
por: Palmer, Ruth H., et al.
Publicado: (2009)

Retraction: A Cross-Talk between TrkB and Ret Tyrosine Kinases Receptors Mediates Neuroblastoma Cells Differentiation
Publicado: (2022)

A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues
por: Luijts, Tom, et al.
Publicado: (2022)

Mutational Signatures Are Critical for Proper Estimation of Purifying Selection Pressures in Cancer Somatic Mutation Data When Using the dN/dS Metric
por: Van den Eynden, Jimmy, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rl45hosh7tt840v1dskq2kgjlp